About Us   Board of Directors

• Richard P. Shanley
• Allen Bloom
• Robert Chefitz
• F. Raymond Salemme

Richard P. Shanley

Richard P. Shanley, CPA, was appointed as a director on September 12, 2007, and as Chairman of the Board on February 11, 2010. Mr. Shanley, a Certified Public Accountant in New York, retired from public accounting at the end of 2006, having completed a 31 year career at Deloitte & Touche LLP and Eisner LLP, with a combined total of 25 years as a Partner at the two firms. During his career, Mr. Shanley served as lead audit partner on numerous engagements for both public and private companies, including those requiring application of Sarbanes Oxley Section 404, as well as public stock offerings, primarily for biotechnology, pharmaceutical and high-tech companies. Mr. Shanley is a recognized authority on financing for emerging growth companies and is a published author of Financing Technology's Frontier. He has spoken at industry meetings and is actively involved in organizations including the Biotech Council of New Jersey, the New York Biotechnology Association, the Connecticut Venture Group, the Biotechnology Industry Organization, and others. Mr. Shanley is currently serving as the chair of the New York State Society of CPA's Professional Ethics Committee. Mr. Shanley currently serves on the Board of Harris & Harris Group, Inc. He earned his B.S. degree from Fordham University and his M.B.A. in Accounting from Long Island University.

Allen Bloom

Allen Bloom, PhD was appointed as a director on September 12, 2007. From 1994 until 2003, Dr. Bloom, a patent attorney, was a partner at the law firm of Dechert LLP, where he served as Co-Chair of the Intellectual Property Group and headed a patent practice group focusing on biotechnology, pharmaceuticals and medical devices. From 1985 until mid-1994, Dr. Bloom was Vice President, General Counsel and Secretary of The Liposome Company, Inc., where he managed patent, regulatory and licensing activities. Before that, Dr. Bloom served as Patent Attorney and Patent Counsel for Pfizer, Inc. and RCA Corporation, respectively. Dr. Bloom currently serves on the Board of the biopharmaceutical company Unigene Laboratories, Inc., where he is Lead Director. He earned his Ph.D. in organic chemistry from Iowa State University, a J.D. degree from New York Law School and a B.S. in Chemistry from Brooklyn College.

Robert Chefitz

F. Raymond Salemme

Dr. Ray Salemme joined the Redpoint Bio team as Chief Executive Officer in June, 2004.  Previously Dr. Salemme was the founder, President and Chief Scientific Officer of 3-Dimensional Pharmaceuticals, Inc. (3DP), a publicly traded biotechnology company founded in 1993, and acquired by Johnson & Johnson in 2003. Dr. Salemme established and directed the technical, operating, business and financing strategies leading to 3DP's successful IPO in 2000, and was co-inventor on 24 of 3DP's key technology patents. Dr. Salemme received the Ernst & Young Entrepreneur of the Year Award for Greater Philadelphia in 1998 for his role in building 3DP.

Prior to 3DP, Dr. Salemme directed research groups for biophysics, computational chemistry, and structure-based drug design at Sterling Winthrop Pharmaceuticals and DuPont Merck Pharmaceuticals. Prior to DuPont Merck, he worked at DuPont Central Research, where he directed molecular design teams for new pharmaceuticals, agrochemicals, and engineered biopolymers.

Dr. Salemme joined DuPont from Genex Corporation, one of the first biotechnology companies, where he pioneered the use of X-ray crystallography and computer-aided molecular design for engineering proteins with novel or enhanced functional properties. Prior to Genex, Dr. Salemme was Professor of Chemistry and Biochemistry at the University of Arizona, where he worked in the area of structural proteomics and determined the 3D X-ray structures of several redox proteins.

Dr. Salemme holds a BA in Molecular Biophysics from Yale University and a PhD in Chemistry from the University of California at San Diego. In addition to his duties at Redpoint Bio, Dr. Salemme participates in advisory committees at National Institutes of Health (NIH), and is a Board member at Gene Network Sciences, a systems biology company.

 

    Redpoint Bio